Anti-inflammatory composition as well as preparation method and application thereof

Abstract

The invention belongs to the technical field of medicines, and particularly relates to an anti-inflammatory composition as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 34 to 50 parts of n-3 fatty acid, 2 to 4 parts of chlorogenic acid, 2 to 4 parts of epigallocatechin gallate and 12 to 24 parts of ginseng peptide. The anti-inflammatory composition prepared from the components and the preparation method has excellent effects of reducing fat and weight, improving metabolic inflammation and protecting liver functions, and has the advantages of high stability and long shelf life.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to an anti-inflammatory composition and a preparation method and application thereof. Background Art

[0002] Chronic inflammation is an inflammatory state that persists at a low level in the body and lasts for a long time. Unlike acute inflammation, it is not short-lived, but persists for weeks, months, or even years. Chronic inflammation can be part of the disease process in the body or the disease itself, especially lifestyle diseases and cancer, which are collectively referred to as non-infectious diseases, of which chronic inflammation is considered to be a cause. Therefore, controlling the balance of inflammatory response is crucial to maintaining health.

[0003] For example, Chinese patent CN100542597C discloses a Chinese medicine preparation process and its use for treating vocal nodules and vocal polyps, and in particular, relates to a Chinese medicine preparation process and its use for treating vocal nodules and vocal polyps. The purpose of the invention is to provide a preparation process of a Chinese medicine preparation for treating vocal nodules and vocal polyps. Another purpose of the invention is to provide an application in drugs for treating vocal nodules and vocal polyps. The preparation process of the present invention is stable and feasible, and the chlorogenic acid content of the finished product is higher than that of the original process, which improves the utilization rate of raw materials and the extraction rate of effective ingredients; the present invention has the function of promoting blood circulation and removing blood stasis, and can reduce whole blood viscosity, plasma viscosity, whole blood reduced viscosity, fibrinogen content and platelet attachment rate; and has an inhibitory effect on the hyperplasia of chronic inflammatory granulation tissue. The patent mentions that chlorogenic acid can be used for chronic inflammation. Patent WO2010018418A1 also mentions that chlorogenic acid, ginseng and epigallocatechin gallate (EGCG) can be used in anti-inflammatory drugs.

[0004] Because there is a close relationship between obesity and inflammation. Obesity is considered to be a chronic low-grade inflammatory state, which can lead to a variety of metabolic diseases such as insulin resistance, type 2 diabetes, and cardiovascular disease. In the obese state, macrophages and other immune cells in adipose tissue release pro-inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), etc. These factors can cause systemic inflammatory responses and further affect metabolic function, leading to a vicious cycle of metabolic function. Therefore, when setting up anti-inflammatory formulas, you should also consider adding ingredients that both reduce weight and fight inflammation.

[0005] As is well known, n-3 fatty acids (eicosapentaenoic acid, docosahexaenoic acid), epigallocatechin gallate (EGCG), and chlorogenic acid can be used in the composition as both anti-inflammatory ingredients and weight-reducing ingredients.

[0006] For example, Chinese patent US20080031967A1 discloses a composition product and method for controlling the weight of mammals. The composition: contains one or more agents that promote fat decomposition and / or regulate thermogenesis. These agents can be soy fat decomposition agents, caffeine, green tea extract, epicatechin, fish oil, conjugated linoleic acid, chickpea extract, etc. A customized adipocyte-based assay is used to identify and test the role of various agents in stimulating fat decomposition in mammalian adipocytes. Experiments have shown that the use of these compositions and products to control the weight of mammals includes the benefits of local weight loss and body shaping. Although the weight loss effect of the composition disclosed in this patent is obvious, it focuses on weight loss and fat reduction, and anti-inflammation is not the focus of the patent, but is only mentioned. If a clear anti-inflammatory effect is required, it is also necessary to consider a composition specially designed for anti-inflammatory.

[0007] In summary, there is an urgent need to develop an anti-inflammatory composition with good matching, few ingredients, targeted anti-inflammatory properties and good weight loss effect. Summary of the invention

[0008] Based on the deficiencies of the prior art, the present invention aims to provide an anti-inflammatory composition with good matching, few ingredients, targetedness, good weight loss and anti-inflammatory effects. The effect experiments have confirmed that the food composition can not only improve metabolic inflammation, but also has excellent fat and weight reduction, and liver function protection effects, and has high stability and a long shelf life.

[0009] In order to achieve the above object, the present invention adopts the following technical solutions:

[0010] In one aspect, the present invention provides an anti-inflammatory composition, comprising the following components by weight: 34-50 parts of n-3 fatty acids, 2-4 parts of chlorogenic acid, 2-4 parts of epigallocatechin gallate and 12-24 parts of ginseng peptide.

[0011] Preferably, the weight ratio of the n-3 fatty acid to epigallocatechin gallate is 50:2-3.

[0012] More preferably, the weight ratio of the n-3 fatty acid to epigallocatechin gallate is 50:3.

[0013] Preferably, the weight ratio of the n-3 fatty acid to the ginseng peptide is 25:6.

[0014] More preferably, the weight ratio of the n-3 fatty acid to epigallocatechin gallate is 1:1.

[0015] Preferably, the anti-inflammatory composition comprises the following components by weight: 50 parts of n-3 fatty acids, 3 parts of chlorogenic acid, 3 parts of epigallocatechin gallate and 12 parts of ginseng peptide.

[0016] In a second aspect, the present invention also provides a method for preparing the anti-inflammatory composition, which specifically comprises: mixing the formulated amounts of n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide to obtain the anti-inflammatory composition.

[0017] In a third aspect, the present invention also provides the use of the anti-inflammatory composition in the preparation of products with anti-inflammatory efficacy.

[0018] In a fourth aspect, the present invention also provides the use of the above anti-inflammatory composition in the preparation of products for weight loss and prevention of weight rebound.

[0019] In a fifth aspect, the present invention further provides a product with anti-inflammatory efficacy, the product comprising the above anti-inflammatory composition, the dosage form of the product being: emulsion, gel, capsule or tablet.

[0020] In a sixth aspect, the present invention further provides a product having the efficacy of reducing weight and preventing weight rebound, the product comprising the above-mentioned anti-inflammatory composition, the dosage form of the product being: emulsion, gel, capsule or tablet.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] (1) The composition of the present invention has excellent effects of reducing fat and weight, improving metabolic inflammation and protecting liver function, and has high stability and a long shelf life.

[0023] (2) The composition of the present invention has few ingredients. It is the first time that n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide are used as an anti-inflammatory formula for weight loss and prevention of weight rebound, and the anti-inflammatory and weight loss effects are obvious. DETAILED DESCRIPTION

[0024] The present invention is further described in detail below in conjunction with specific embodiments. The embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention is described in detail with reference to the following embodiments, a person of ordinary skill in the art should understand that the technical solutions described in the following embodiments can still be modified, or some of the technical features can be replaced by equivalents; and these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

[0025] In the present invention, detailed information of n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide is shown in Table 1.

[0026] Table 1

[0027]

[0028]

[0029] Example 1

[0030] An anti-inflammatory composition

[0031] The composition consists of the following components by weight: 50 parts of n-3 fatty acid, 3 parts of chlorogenic acid, 3 parts of epigallocatechin gallate and 12 parts of ginseng peptide.

[0032] A method for preparing an anti-inflammatory composition

[0033] The anti-inflammatory composition is obtained by mixing n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide.

[0034] Example 2

[0035] An anti-inflammatory composition

[0036] The composition consists of the following components by weight: 50 parts of n-3 fatty acid, 2 parts of chlorogenic acid, 4 parts of epigallocatechin gallate and 12 parts of ginseng peptide.

[0037] A method for preparing an anti-inflammatory composition

[0038] The anti-inflammatory composition is obtained by mixing n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide.

[0039] Example 3

[0040] An anti-inflammatory composition

[0041] The composition consists of the following components by weight: 50 parts of n-3 fatty acid, 4 parts of chlorogenic acid, 2 parts of epigallocatechin gallate and 12 parts of ginseng peptide.

[0042] A method for preparing an anti-inflammatory composition

[0043] The anti-inflammatory composition is obtained by mixing n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide.

[0044] Example 4

[0045] An anti-inflammatory composition

[0046] The composition consists of the following components by weight: 50 parts of n-3 fatty acid, 4 parts of chlorogenic acid, 4 parts of epigallocatechin gallate and 24 parts of ginseng peptide.

[0047] A method for preparing an anti-inflammatory composition

[0048] The anti-inflammatory composition is obtained by mixing n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide.

[0049] Example 5

[0050] An anti-inflammatory composition

[0051] The composition consists of the following components by weight: 34 parts of n-3 fatty acid, 2 parts of chlorogenic acid, 2 parts of epigallocatechin gallate and 12 parts of ginseng peptide.

[0052] A method for preparing an anti-inflammatory composition

[0053] The anti-inflammatory composition is obtained by mixing n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide.

[0054] Comparative Example 1

[0055] An anti-inflammatory composition

[0056] The difference from Example 1 is that the ingredients are different but the total number of parts is the same, which is only 68 parts of n-3 fatty acids.

[0057] Comparative Example 2

[0058] The difference from Example 1 is that the ingredients are different but the total parts are the same, only 64 parts of n-3 fatty acids and 4 parts of chlorogenic acid.

[0059] A method for preparing an anti-inflammatory composition

[0060] The anti-inflammatory composition is obtained by mixing n-3 fatty acids and chlorogenic acid.

[0061] Comparative Example 3

[0062] The difference from Example 1 is that the ingredients are different but the total parts are the same, 60 parts of n-3 fatty acids, 4 parts of chlorogenic acid and 4 parts of epigallocatechin gallate.

[0063] A method for preparing an anti-inflammatory composition

[0064] The anti-inflammatory composition is obtained by mixing n-3 fatty acids, chlorogenic acid and epigallocatechin gallate.

[0065] Comparative Example 4

[0066] An anti-inflammatory composition

[0067] The composition consists of the following components by weight:

[0068] 25 parts of n-3 fatty acids, 5 parts of chlorogenic acid, 28 parts of epigallocatechin gallate and 10 parts of ginseng peptide.

[0069] A method for preparing an anti-inflammatory composition

[0070] The anti-inflammatory composition is obtained by mixing n-3 fatty acids, chlorogenic acid 1, epigallocatechin gallate and ginseng peptide.

[0071] Effect experiment

[0072] 1. Weight loss experiment

[0073] 1.1 Experimental method: Fat and weight loss test in mice

[0074] Six-week-old C57BL / 6J male mice (Vital River Laboratory Animal Technology, Beijing, China) were selected and kept in a specific pathogen-free standard facility, with 3 mice per cage. The mice without modeling were the blank control group and fed with standard feed; the obese mice for modeling were divided into the model control group, Example 1-5 groups, and Comparative Example 1-4 groups, with 6 mice in each group. After 12 weeks of feeding with 60% high-fat feed in the model control group, the body weight was higher than 20% of the average body weight of the blank control group mice, indicating that the obesity modeling was successful. The obese model group continued to be fed with high-fat feed for 8 weeks, and the blank control group was fed with standard feed throughout the whole process.

[0075] After 20 weeks, each group of mice in the embodiment and comparative example was given high-fat or standard feed and different components by gavage (after dissolving with 10mL of normal saline and calculating the dose by weight, the anti-inflammatory composition was gavaged in the stomach) according to different groups every day after the obesity model was successfully established, and the intervention was continued for 8 weeks. Among them, in order to observe the factors of the mouse's own metabolism leading to weight loss, a control group was set up, and 1 / 3 of the mice in Example 1 were fed with standard feed, without gavage of anti-inflammatory composition, and gavage of equal amount of normal saline. The weight and food intake of each mouse were recorded twice a week. After the feeding was completed, the body composition of the mouse was detected, and blood was collected from the retroorbital cavity after anesthesia. After separating the serum, IL-1β, IL-6, TNF-α, blood lipids, and liver and kidney function were detected. IL-1β, IL-6 and TNF-α are three important cytokines that play a key role in the immune system, especially in inflammatory response and immunoregulation.

[0076] 1.2 Experimental results

[0077] The experimental results of mice after 8 weeks of intervention are shown in Table 2 below.

[0078] Table 2

[0079]

[0080]

[0081] Note: Compared with the model control group, #P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001; compared with the Example 1 group, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0082] 1.3 Experimental Results Analysis

[0083] It can be seen from Examples 1-5 that the composition obtained by the proportions of the components and the preparation method of Example 1 has the best fat-reducing and anti-inflammatory effects.

[0084] It can be seen from Comparative Examples 1-3 that no matter which component is missing from the composition, the effects on body weight, body fat and TNF-α are weak, indicating that the four components can work together to achieve the best weight loss, fat reduction and anti-inflammatory effects. It can be seen from Comparative Example 4 that the anti-inflammatory and weight loss and fat reduction effects will be better if the composition ratios of the four components are within the protection scope of the present invention.

[0085] 2. Experiment on preventing weight rebound

[0086] 2.1 Experimental methods:

[0087] The above embodiments and comparative examples were applied to a weight rebound mouse model. The model control group was fed with a 60% high-fat diet for 8 weeks and then alternately fed with a high-fat diet and a normal diet for 2 weeks each for a total of 8 weeks. The blank control group was fed with a standard diet throughout the whole process. After 8 weeks, the weight, body fat percentage, and TNF-α, TG, IL-1β, and IL-6 concentrations of the mice were measured.

[0088] 2.2 Experimental results:

[0089] The experimental results are shown in Table 3 below.

[0090] Table 3

[0091]

[0092] Note: Compared with the model control group, #P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001; compared with the Example 1 group, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0093] 2.3 Experimental Results Analysis

[0094] As can be seen from Table 2 above, the embodiment group can significantly prevent weight rebound compared with the comparative example group.

[0095] In summary, the anti-inflammatory composition composed of the components within the scope of protection of the present invention synergizes with each other and has obvious effects in reducing fat and weight, anti-inflammation and preventing weight rebound, and n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide are indispensable.

Claims

1. An anti-inflammatory composition, characterized in that The anti-inflammatory composition comprises the following components by weight: 34-50 parts of n-3 fatty acid, 2-4 parts of chlorogenic acid, 2-4 parts of epigallocatechin gallate and 12-24 parts of ginseng peptide.

2. The anti-inflammatory composition according to claim 1, characterized in that The weight ratio of the n-3 fatty acid to epigallocatechin gallate is 50:2-3.

3. The anti-inflammatory composition according to claim 1, characterized in that The weight ratio of the n-3 fatty acid to the ginseng peptide is 25:

6.

4. The anti-inflammatory composition according to claim 1, characterized in that The weight ratio of chlorogenic acid to epigallocatechin gallate is 1:

1.

5. The anti-inflammatory composition according to claim 1, characterized in that The composition comprises the following components by weight: 50 parts of n-3 fatty acid, 3 parts of chlorogenic acid, 3 parts of epigallocatechin gallate and 12 parts of ginseng peptide.

6. The method for preparing the anti-inflammatory composition according to any one of claims 1 to 5, characterized in that: The anti-inflammatory composition is obtained by mixing the n-3 fatty acids, chlorogenic acid, epigallocatechin gallate and ginseng peptide in the prescribed amounts.

7. Use of the anti-inflammatory composition according to any one of claims 1 to 5 in the preparation of a product with anti-inflammatory efficacy.

8. Use of the anti-inflammatory composition according to any one of claims 1 to 5 in the preparation of a product having the efficacy of reducing weight and preventing weight rebound.

9. A product with anti-inflammatory effect, characterized in that: The anti-inflammatory composition comprises the anti-inflammatory composition according to any one of claims 1 to 5, wherein the dosage form of the product is: emulsion, gel, capsule or tablet.

10. A product with the effect of reducing weight and preventing weight rebound, characterized in that: The anti-inflammatory composition comprises the anti-inflammatory composition according to any one of claims 1 to 5, wherein the dosage form of the product is: emulsion, gel, capsule or tablet.

Images